Literature DB >> 6300194

Receptor-mediated catabolism of low density lipoprotein in man. Quantitation using glucosylated low density lipoprotein.

Y A Kesaniemi, J L Witztum, U P Steinbrecher.   

Abstract

Low density lipoprotein (LDL) catabolism occurs by LDL receptor-dependent and LDL receptor-independent pathways. We have shown previously that nonenzymatic glucosylation of LDL in the presence of cyanoborohydride irreversibly blocks the lysine residues of LDL. Glucosylated LDL (GLC-LDL) was not degraded by the LDL receptor of fibroblasts, and its degradation by macrophages was similar to that of native LDL. This suggested that GLC-LDL should be a good tracer of LDL receptor-independent catabolism, and if combined with a tracer of total LDL catabolism, should enable one to calculate the extent of LDL receptor-dependent catabolism. To determine the contribution of each pathway in man, we prepared (125)I-GLC-LDL and (131)I-control LDL and simultaneously determined the fractional catabolic rate (FCR) of each tracer in four subjects. In preliminary experiments, we showed that the conditions for glucosylation did not affect LDL turnover. In the four subjects, the FCR for total LDL catabolism ranged from 0.345 to 0.724 d(-1) with a mean of 0.57+/-0.16 d(-1). The FCR of GLC-LDL varied from 0.071 to 0.141 d(-1) with a mean of 0.11+/-0.03 d(-1). The latter is similar to the FCR reported for native LDL in subjects with homozygous familial hypercholesterolemia, supporting the interpretation that GLC-LDL traces only the receptor-independent pathway. Despite the wide range of total LDL catabolism in these subjects. LDL receptor-independent catabolism accounted for only 19.5-20.6% of total catabolism. In turn, LDL receptor-dependent catabolism accounted for 80% of total clearance in each person. Furthermore, while the decay curve of LDL showed the usual biphasic pattern, the decay curve of GLC-LDL was monoexponential in each subject even when followed for as long as 48 d. This suggests that LDL receptor activity is responsible for the biphasic nature of LDL decay. These studies emphasize the central role of LDL receptor activity in normal LDL metabolism in man.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6300194      PMCID: PMC436952          DOI: 10.1172/jci110849

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  The theory of tracer experiments with 131I-labelled plasma proteins.

Authors:  C M MATTHEWS
Journal:  Phys Med Biol       Date:  1957-07       Impact factor: 3.609

2.  Flotation rates, molecular weights and hydrated densities of the low-density lipoproteins.

Authors:  F T Lindgren; L C Jensen; R D Wills; N K Freeman
Journal:  Lipids       Date:  1969-09       Impact factor: 1.880

Review 3.  Hepatic catabolism of low density lipoprotein: mechanisms and metabolic consequences.

Authors:  A D Attie; R C Pittman; D Steinberg
Journal:  Hepatology       Date:  1982 Mar-Apr       Impact factor: 17.425

4.  Effects of polyunsaturated fats on lipid metabolism in patients with hypertriglyceridemia.

Authors:  S M Grundy
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

5.  Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia.

Authors:  D W Bilheimer; J L Goldstein; S M Grundy; M S Brown
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

6.  Metabolic studies in familial hypercholesterolemia. Evidence for a gene-dosage effect in vivo.

Authors:  D W Bilheimer; N J Stone; S M Grundy
Journal:  J Clin Invest       Date:  1979-08       Impact factor: 14.808

7.  Inhibition of receptor-mediated clearance of lysine and arginine-modified lipoproteins from the plasma of rats and monkeys.

Authors:  R W Mahley; K H Weisgraber; G W Melchior; T L Innerarity; K S Holcombe
Journal:  Proc Natl Acad Sci U S A       Date:  1980-01       Impact factor: 11.205

8.  Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity.

Authors:  J L Witztum; E M Mahoney; M J Branks; M Fisher; R Elam; D Steinberg
Journal:  Diabetes       Date:  1982-04       Impact factor: 9.461

9.  Measurement of receptor-independent lipoprotein catabolism using 1,2 cyclohexanedione-modified low density lipoprotein.

Authors:  H R Slater; C J Packard; J Shepherd
Journal:  J Lipid Res       Date:  1982-01       Impact factor: 5.922

10.  Metabolism of homologous and heterologous lipoproteins by cultured rat and human skin fibroblasts.

Authors:  C A Drevon; A D Attie; S H Pangburn; D Steinberg
Journal:  J Lipid Res       Date:  1981-01       Impact factor: 5.922

View more
  37 in total

1.  Probing of the expression of the low-density lipoprotein receptor in vivo using an anti-receptor monoclonal antibody.

Authors:  E Gherardi; D E Bowyer; C Fitzsimmons; T Le Cras; A Hutchings; G Butcher
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

Review 2.  Lipoprotein alterations in diabetes mellitus.

Authors:  G M Kostner; I Karádi
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

3.  Receptor-independent low density lipoprotein transport in the rat in vivo. Quantitation, characterization, and metabolic consequences.

Authors:  D K Spady; S D Turley; J M Dietschy
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 14.808

4.  Interaction of dietary cholesterol and triglycerides in the regulation of hepatic low density lipoprotein transport in the hamster.

Authors:  D K Spady; J M Dietschy
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

5.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes.

Authors:  D W Bilheimer; S M Grundy; M S Brown; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

Review 6.  Pathophysiology of human lipoprotein receptors: clinical consequences of a cellular defect.

Authors:  J Shepherd; C J Packard
Journal:  J Clin Pathol       Date:  1984-01       Impact factor: 3.411

7.  Technetium-99m labelled LDL as a tracer for quantitative LDL scintigraphy. I. Tracer purification, in vitro and in vivo long-term stability, in vitro validation and biodistribution.

Authors:  T Leitha; M Hermann; M Hüttinger; P Angelberger; R Dudczak
Journal:  Eur J Nucl Med       Date:  1993-08

8.  Evidence for sterol-independent regulation of low-density lipoprotein receptor activity in Hep-G2 cells.

Authors:  J L Ellsworth; C Chandrasekaran; A D Cooper
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

9.  Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects.

Authors:  M I Uusitupa; L K Niskanen; O Siitonen; E Voutilainen; K Pyörälä
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

10.  Lipid profile in oral submucous fibrosis.

Authors:  Ravi Mehrotra; Shruti Pandya; Ajay Kumar Chaudhary; Himanshu Pratap Singh; Ritesh Kumar Jaiswal; Mangal Singh; S C Gupta; Mamta Singh
Journal:  Lipids Health Dis       Date:  2009-07-24       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.